The New England Journal of Medicine
10 Shattuck Street
Boston
Massachusetts
02115-6094
United States
Tel: 617-734-9800
Fax: 617-739-9864
Website: http://www.nejm.org/
313 articles about The New England Journal of Medicine
-
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
3/3/2022
The New England Journal of Medicine published detailed results from a Phase 3 trial evaluating nirsevimab, the first investigational long-acting antibody designed to protect all infants across the respiratory syncytial virus season with a single dose.
-
New England Journal of Medicine publishes positive final results from phase 1/2a study of BIVV001 in people with severe haemophilia A
9/10/2020
BIVV001 is the first investigational factor VIII therapy independent of von Willebrand factor and has the potential to transform replacement therapy for people with haemophilia A
-
New Data Show 340B Hospitals Are Reimbursed on Average Three Times What They Pay for Medicines
12/17/2019
Hospitals participating in the 340B drug pricing program are reimbursed for physician-administered medicines at a rate that is on average three times what they paid to acquire the medicine, according to a new analysis conducted by Milliman and commissioned by the Pharmaceutical Research and Manufacturers of America.
-
Another scientific paper has been retracted by the New England Journal of Medicine. The noted journal said it retracted a paper on evidence of human lung stem cells following an investigation that revealed images used in the article had been manipulated.
-
NEJM Group Announces Jeffrey Drazen, M.D., to Retire
9/27/2018
NEJM Group announced Thursday that Jeffrey M. Drazen, M.D., Editor-in-Chief of the New England Journal of Medicine, will retire within the next year.
-
John Theurer Cancer Center Release: Critical Hodgkin's Lymphoma Cancer Study Published in the New England Journal of Medicine
1/19/2018
John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center participated in a pivotal clinical trial for Hodgkin's Lymphoma.
-
John Theurer Cancer Center Release: Pivotal CAR-T Therapy Cancer Study Published in the New England Journal of Medicine
12/27/2017
John Theurer Cancer Center at Hackensack University Medical Center is the only New Jersey center that participated in a pivotal clinical trial of a groundbreaking cancer treatment, CAR-T Cell therapy, which genetically modifies a patient's immune system to attack cancer cells.
-
Pfizer's Phase III TRUMENBA (Meningococcal Group B Vaccine) Data Published in New England Journal of Medicine Demonstrate the Vaccine’s Immunogenicity
12/14/2017
These studies met all five co-primary immunogenicity endpoints against a panel of diverse test strains.
-
Stryker Announces Publication of the DAWN Trial Results in the New England Journal of Medicine
11/13/2017
The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy.
-
The New England Journal of Medicine Publishes First Phase III Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
11/2/2017
SPINRAZA demonstrated a favorable benefit-risk profile.
-
AveXis Announces New England Journal of Medicine Publication of Phase I Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1
11/2/2017
The NEJM publication provides detailed data as of August 7, 2017, from the Phase 1, open-label, dose-escalating study, designed to evaluate the safety and tolerability of AVXS-101 in patients with SMA Type 1.
-
Nobles Medical Technology II Release: NobleStitch EL Closure Data Presented At CSI UCSF Congress Compares Published RESPECT And CLOSURE PFO Data In The New England Journal of Medicine To NobleStitch
10/10/2017
-
Heartstitch GmbH Announces Noblestitch EL Closure Data Compared To Published PFO Clinical Trials "RESPECT" And "CLOSURE" In The New England Journal of Medicine
10/10/2017
-
Inovio Pharma’s Positive Zika Vaccine Clinical Study Data Published In The New England Journal of Medicine
10/5/2017
-
Lexicon Pharma Release: The New England Journal of Medicine Publishes Data From Phase III InTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes
9/13/2017
-
Amgen Release: EVENITY (romosozumab) ARCH Study Results Published In The New England Journal of Medicine
9/12/2017
-
Juno And The New England Journal of Medicine Release: Anti-CD19 CAR T Cells In CNS Diffuse Large-B-Cell Lymphoma
8/24/2017
-
Amgen Release: Repatha (Evolocumab) Phase III Cognitive Function Study Results Published In The New England Journal of Medicine
8/17/2017
-
Positive Phase III Results Of Genentech’s Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In The New England Journal of Medicine
7/27/2017
-
Chugai Pharma's Bispecific Antibody "Emicizumab" Global Phase III Data In Patients With Haemophilia A With Inhibitors Published In The New England Journal of Medicine Online
7/10/2017